Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

tients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

Full prescribing information about FENTORA, including boxed warning, is available from http://www.FENTORA.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. Cephalon has delivered a seven-year compound annual growth rate (CAGR) through 2006 greater than 75 percent and 2006 revenue of $1.760 billion. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... DIEGO , July 22, 2014  Halozyme Therapeutics, ... it has resumed enrollment and dosing of patients in ... in patients with pancreatic cancer under the revised clinical ... is an investigational PEGylated form of Halozyme,s proprietary recombinant ... tumors that accumulate hyaluronan. "Our diligent ...
(Date:7/22/2014)... YORK , July 22, 2014 /PRNewswire-iReach/ -- ... New York ), a nationally and ... for patients requiring reproductive assistance, is pleased to announce ... Corps and Compassionate Care Programs to recognize the sacrifices ... The Compassionate Corps Program will allow qualifying ...
(Date:7/22/2014)... , July 22, 2014 The steady ... is spreading to previously rep-friendly specialties, according to ... and marketing consulting firm ZS Associates.      ... 200 U.S. pharmaceutical sales teams. The report examines ... meet with the pharmaceutical sales reps who visit ...
Breaking Medicine Technology:Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5
... ("Senesco" or the "Company") (NYSE Amex: SNT ) ... conducted in Dr. William Scheld,s lab at the University of ... against Senesco,s Factor 5A gene had a 52% survival rate as ... treatment or a control siRNA.A total of 73 mice were infected ...
... announced today that eleven presentations or publications on pre-clinical ... in several major tumor types will be made during ... Meeting, May 29-June 2, in Orlando, Florida. Abstracts ... http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ) Prostate ...
Cached Medicine Technology:Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
(Date:7/22/2014)... Legislation backed by the drugstore lobby ... Act of 2014”) championing so-called “any willing pharmacy” ... availability of lower cost preferred pharmacy networks and ... next 10 years, according to new research from ... Management Association (PCMA). , The drugstore lobby targets ...
(Date:7/22/2014)... -- New guidelines on cholesterol treatment and cardiovascular risk ... risk of dying from atherosclerotic cardiovascular disease or of ... with a similar risk profile (based on age, smoking ... of this finding for when and how aggressively to ... Journal of Men,s Health , a peer-reviewed publication ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... (HealthDay News) -- One of the largest studies ever ... has uncovered 83 new sites on chromosomes that harbor ... by an international team of researchers, now bring the ... disorder to 108. Although these schizophrenia-associated genes ... to predict who will or will not develop the ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... brain cells suddenly went rogue and decided to become fat ... early in an organism,s development, cells make firm and more-or-less ... say, skin cells, brain cells or, well, fat cells. ... the possible candidates encoded in a cell,s genes, the cell ...
... SUNDAY, March 20 (HealthDay News) -- People with asthma may ... according to a new study that looked at the relationship ... which looked at medical records from the late 1960s through ... illness among asthmatics than other people. Researchers led by ...
... ill in Britain, according to new research published today by ... of almost 800 patients with severe mental illness such as ... or obese, and a disproportionate number suffered from diabetes, heart ... results of the two-year project in Kent are published today ...
... HealthDay Reporter , SATURDAY, March 19 (HealthDay News) -- ... quickly as experts previously have believed. In a study ... third outgrew it within 30 months. But that finding ... higher percentage of children outgrowing the allergy fairly quickly, said ...
... Today, during the 89th General Session & Exhibition of ... with the 40th Annual Meeting of the American Association ... the Canadian Association for Dental Research, lead researcher F. ... study titled "Biodegradable Tooth-binding Micelles Inhibit Streptococcus mutans ...
... 18, 2011)--The growing concern surrounding the release of ... in Japan has raised fears of radiation exposure ... plume of radioactivity crossing the Pacific Ocean. To ... American Association of Clinical Endocrinologists (AACE), the American ...
Cached Medicine News:Health News:Stanford researchers discover molecular determinant of cell identity 2Health News:Stanford researchers discover molecular determinant of cell identity 3Health News:Stanford researchers discover molecular determinant of cell identity 4Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 2Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 3Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 4Health News:Life expectancy of severely mentally ill dramatically reduced due to poor physical health 2Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 2Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 3Health News:Biodegradable tooth-binding micelles inhibit Streptococcus mutans biofilm growth 2Health News:Radiation risks to health: A joint statement from leading scientific experts 2
... The Answer to Micro-Incision Cataract ... Technology With its unique double-step ... knife is ideal for MICS. ... reproducible incisions that allow you ...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: